Company Profile

Phathom Pharmaceuticals Stock Price, News & Catalysts

Ticker:
PHAT
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

5.08 USD (-4.15%)

Close

Last updated: November 19, 2026

770M USD

Market cap

Why the stock is moving

Following the latest company update, “Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously”, PHAT closed down 4.15% at $5.08 on Nov 19, 2026. The move occurred in the trading session associated with this company update.

Company overview

Gastrointestinal Medicines

Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker.

VOQUEZNA Franchise

VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux disease, healing and maintenance of erosive GERD, and as dual- or triple-drug packs for Helicobacter pylori infection. Its mechanism provides rapid and durable acid suppression distinct from proton-pump inhibitors.

Eosinophilic Esophagitis Development

The Phase 2 pHalcon-EoE-201 trial is evaluating VOQUEZNA in eosinophilic esophagitis. This program tests whether strong acid suppression can benefit a chronic inflammatory esophageal disease and extend the franchise into another specialist-treated indication.

As-Needed NERD Program

Phathom is developing VOQUEZNA for as-needed treatment of non-erosive gastroesophageal reflux disease through the registrational pHalcon-NERD-302 study. The program is intended to offer an intermittent alternative to continuous daily acid suppression.

Future catalysts

  • Topline results from the blinded treatment portion of the Phase 2 pHalcon-EoE-201 trial in the fourth quarter of 2026.
  • Topline results from the registrational Phase 3 pHalcon-NERD-302 as-needed treatment study in the first quarter of 2028.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals (PHAT) most recently closed at 5.08 USD, a -4.15% move versus the previous session.

What is the market cap of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals currently has a market capitalization of 770M USD on BioPharmSignal.

What does Phathom Pharmaceuticals do?

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux...

On which exchange is PHAT stock listed?

Phathom Pharmaceuticals (PHAT) is associated with NASDAQ, United States, Biopharma.

What is NERD-302?

Topline results from the registrational Phase 3 pHalcon-NERD-302 as-needed treatment study in the first quarter of 2028.

Which conditions is Phathom Pharmaceuticals targeting with NERD-302?

Topline results from the registrational Phase 3 pHalcon-NERD-302 as-needed treatment study in the first quarter of 2028.

How does Phathom Pharmaceuticals describe recent progress with NERD-302?

Topline results from the registrational Phase 3 pHalcon-NERD-302 as-needed treatment study in the first quarter of 2028.

What is Gastrointestinal?

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases.